<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00144508</url>
  </required_header>
  <id_info>
    <org_study_id>MRA012JP</org_study_id>
    <nct_id>NCT00144508</nct_id>
  </id_info>
  <brief_title>Phase III Comparative Study(Open-Label) of MRA for Rheumatoid Arthritis(RA)</brief_title>
  <official_title>An Open-Label, Phase III Study to Evaluate the Efficacy and Safety of MRA in Patients With RA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chugai Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chugai Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate clinical efficacy and tolerability of MRA, patients with RA are randomized to
      receive either MRA or conventional DMARDs.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">February 2006</completion_date>
  <primary_completion_date type="Actual">May 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the erosion score, as determined by the modified Sharp method.</measure>
    <time_frame>week 52</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency and severity of adverse events and adverse drug reactions</measure>
    <time_frame>throughout study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the erosion score</measure>
    <time_frame>week 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the joint space narrowing score and total Sharp score</measure>
    <time_frame>week 28, 52</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">306</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>continue current treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MRA (Tocilizumab)</intervention_name>
    <description>8mg /kg /4week for 52 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>current treatment</intervention_name>
    <description>continue current treatment</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Diagnosed as having RA, on the basis of the criteria stipulated by the American
             Conference on Rheumatism (ACR) in 1987.

          -  With RA that has continued for at least 6 months but less than 5 years, with the date
             of first appearance being taken as the date of RA diagnosis.

          -  Active RA despite at least one DMARD or immunosuppressant. Active disease is defined
             as having at least 6 tender and 6 swollen joints among 49 and 46 joints stipulated by
             the Japanese Rheumatism Foundation's Drug Evaluation Committee and ESR at least 30
             mm/hr and CRP not less than 2.0mg/dL.

        Exclusion criteria

          -  Shown to have class-IV Steinbrocker's functional activity in an evaluation carried out
             within 4 weeks before administration of the study drug.

          -  Treated with drugs that delay joint destruction (infliximab, etanercept, leflunomide,
             etc.) within 3 months before administration of the study drug.

          -  The oral corticosteroid dose (prednisolone equivalent of up to 10 mg/day)has not been
             fixed 2 weeks before administration of the study drug.

          -  Subjected to any of the following within 4 weeks before administration of the study
             drug: (i) Change in dosage of currently administered DMARDs and/or immunosuppressive
             agents. (ii) Plasma exchange method. (iii) Surgical treatment (operations, etc.).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Takahiro Kakehi</last_name>
    <role>Study Director</role>
    <affiliation>Chugai Pharmaceutical</affiliation>
  </overall_official>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2005</study_first_submitted>
  <study_first_submitted_qc>September 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2005</study_first_posted>
  <last_update_submitted>January 30, 2009</last_update_submitted>
  <last_update_submitted_qc>January 30, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2009</last_update_posted>
  <responsible_party>
    <name_title>Chugai Pharmaceutical</name_title>
    <organization>Chugai Pharmaceutical</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

